General Information

We are a clinical-stage gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Our initial product candidate, AVXS-101, is our proprietary gene therapy product candidate currently in a Phase 1 clinical trial for the treatment of spinal muscular atrophy, or SMA, Type 1, the leading genetic cause of infant mortality. SMA Type 1 is a lethal genetic disorder characterized by motor neuron loss and associated muscle deterioration, resulting in mortality or the need for permanent ventilation support before the age of two for greater than 90% of patients.

Employees: 18
Founded: 2010
Contact Information
Address 2275 Half Day Rd, Suite 160 Bannockburn, IL 60015, US
Phone Number (847) 572-8280
Web Address http://www.avexis.com
View Prospectus: AveXis
Financial Information
Market Cap $448.0mil
Revenues $0.0 mil (last 12 months)
Net Income $-29.0 mil (last 12 months)
IPO Profile
Symbol AVXS
Exchange NASDAQ
Shares (millions): 4.8
Price range $20.00 - $20.00
Est. $ Volume $95.0 mil
Manager / Joint Managers Goldman Sachs/ Jefferies
CO-Managers BMO Capital Markets/ Chardan
Expected To Trade: 2/11/2016
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change